ClinicalTrials.gg
TerminatedNCT03773302Updated May 8, 2024Results posted

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

A Phase 3 interventional study of BGJ398 and Gemcitabine in Advanced Cholangiocarcinoma and FGFR2 Gene Mutation, sponsored by QED Therapeutics, Inc.. Terminated at 116 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by QED Therapeutics, Inc. (part of BridgeBio) · Phase 3, Interventional, and Treatment

Why this study was terminated
The sponsor has decided to close the study due to the discontinuation of infigratinib development in oncology within the sponsor's territory. The discontinuation of the study was not due to safety issues.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 111 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Enrollment
134th of 279
48 · median 44
Started
2019
with 25 others
Phase 3
18 of 328
3 open now
Registered
144th of 328
by date

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 134th largest by enrollment of the 279 interventional ones that give a count, is one of 26 that started in 2019, is one of 18 in phase 3, and was the 144th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma. The purpose of the study is to evaluate the efficacy and safety of the investigational agent oral infigratinib vs standard of care chemotherapy (gemcitabine plus cisplatin) in first-line treatment of participants with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion/rearrangement. Subjects will be randomized 2:1 to receive infigratinib or gemcitabine plus cisplatin.

03

Conditions studied

  • Advanced Cholangiocarcinoma
  • FGFR2 Gene Mutation

Browse trials for

Keywords

  • cholangiocarcinoma
  • unresectable cholangiocarcinoma
  • metastatic cholangiocarcinoma
  • fibroblast growth factor receptor inhibitor
  • FGFR2
  • FGFR2 gene fusions/translocations
  • BGJ398
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed unresectable locally advanced or cholangiocarcinoma. Participants with gallbladder cancer or ampulla of Vater carcinoma are not eligible
  • Have written documentation of local laboratory or central laboratory determination of a known or likely activating FGFR2 fusion/rearrangement from a sample collected before randomization
  • Have an sample available with sufficient tumor content for FGFR2 fusion/rearrangement molecular testing by the central laboratory. However, if an archival tumor tissue sample is not available, or does not meet requirements for central testing a newly obtained (before randomization) tumor biopsy may be submitted instead. If a prestudy written documentation of FGFR2 fusion/rearrangement in tumor tissue is available from the central laboratory, an additional tumor sample does not need to be submitted.
  • Have an (ECOG) performance status 0 or 1
  • Are able to swallow and retain oral medication
  • Are willingness to avoid pregnancy or father children

Exclusion criteria

Exclusion Criteria:

  • Received treatment with any systemic anti-cancer therapy for unresectable locally advanced or cholangiocarcinoma, with following exceptions

    1. Prior or adjuvant therapy is permitted if completed > 6 months after the last dose of neoadjuvant or adjuvant therapy.
    2. One cycle of gemcitabine-based chemotherapy for locally advanced or metastatic cholangiocarcinoma is permitted before randomization
  • History of a liver transplant
  • Received previously or currently is receiving treatment with a mitogen activated protein kinase kinase (MEK) or selective FGFR inhibitor
  • Have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral infigratinib (such as, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).
  • Current evidence of endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis etc.
  • History and/or current evidence of extensive tissue calcification including, but not limited to, the soft tissue, kidneys, intestine, myocardium, vascular system and lung with the exception of calcified lymph nodes, minor pulmonary parenchymal calcifications, and asymptomatic coronary calcification
  • Current evidence of corneal or retinal disorder/keratopathy
  • Receiving and continued treatment or are planning to receive agents or consuming foods that are known moderate or strong inducers or inhibitors of and medications which increase serum phosphorus and/or calcium concentration
  • or uncontrolled cardiac disease
  • Recent (≤ 3 months prior to first dose of study drug) or stroke
  • Severe hearing loss
  • Severe neuropathy
  • History of another primary within 3 years except adequately treated in-situ carcinoma of the cervix or non-melanoma skin cancer or other curatively treated malignancy that is not expected to require treatment
  • Pregnant or breastfeeding
  • Have known microsatellite instability-high (MSI-H) disease and the decision is made by the treating investigator that an alternative, non-study therapy is warranted according to standard of care.
  • Have any known to gemcitabine, cisplatin, calcium-lowering agents, infigratinib, or their
  • Have any to cisplatin or gemcitabine treatment according to local labeling or standard institutional practice.
  • Have taken any Chinese herbal medicine or Chinese patent medicine treatments with anticancer activity within 14 days of the first dose of study drug.
  • Have received a within 30 days before the first dose of study drug or are planning to receive a live vaccine during participation in this study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Infigratinib (BGJ398) 125 mg

    Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.

    Drug: BGJ398

  • Active comparator
    Gemcitabine + Cisplatin

    Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib if certain criteria are met.

    Drug: Gemcitabine · Drug: Cisplatin

Interventions

  • DrugBGJ398

    Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.

    Also known as: Infigratinib

  • Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.

  • Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (Central Imaging Assessment)

    Defined as the time from randomization until date of disease progression by blinded independent central imaging assessment (Response Evaluation Criteria in Solid Tumors \[RECIST\] v. 1.1) or death, whichever occurs first.

    Time frame: From the time of randomization to end of treatment due to confirmed disease progression or death. Note: PFS is an event driven endpoint. Subjects without confirmed disease progression at the end of study were censored at their last valid tumor assessment.

Secondary outcomes

  1. Overall Survival (OS) in Participants Treated With Infigratinib Versus Gemcitabine With Cisplatin

    OS by investigator assessment, defined as time from date of randomization until death due to any cause

    Time frame: From the time of randomization to time of death. Note: OS is an event driven endpoint. Subjects who had not died (no record of death) or were lost to follow-up were censored at the date of last known to be alive.

  2. Investigator Assessed Progression Free Survival in Participants Treated With Infigratinib Compared to Gemcitabine and Cisplatin

    Defined as the time from randomization until date of disease progression by site investigator (RECIST v1.1) or death, whichever occurs first.

    Time frame: From the time of randomization to end of treatment due to confirmed disease progression or death. Note: PFS is an event driven endpoint. Subjects without confirmed disease progression at the end of study were censored at their last valid tumor assessment.

  3. Overall Response Rate (ORR) Determined by Blinded Independent Central (BICR) and Investigator Assessment

    ORR is defined as the proportion of subjects with a best overall response (BOR) of either confirmed partial response (PR) or confirmed complete response (CR) as assessed by BICR and the investigator according to RECIST v1.1 among patients with measurable disease at baseline

    Time frame: From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).

  4. Best Overall Response (BOR) Determined by Blinded Independent Central Assessment and the Investigator.

    BOR was defined as the best response a subject ever achieved after study treatment prior to crossover and any subsequent anticancer therapy, complete response (CR) and partial response (PR) were claimed only if the criteria for each were met at a subsequent time point at least 4 weeks apart. In the case of stable disease (SD), measurements must have met the SD criteria at least once post-baseline no less than 6 weeks from the randomization date.

    Time frame: From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).

  5. Duration of Response (DOR) Determined by Blinded Independent Central Assessment and the Investigator.

    DOR is defined as the time from initiation of confirmed partial response (PR) or confirmed complete response (CR) to the time of confirmed progressive disease (PD) or death. If subjects do not reach PD or death before crossover, the DOR is censored at the last valid tumor assessment before crossover.

    Time frame: From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).

  6. Disease Control Rate (DCR=PR+CR+SD) Determined by Blinded Independent Central Assessment and the Investigator.

    DCR is defined as the proportion of subjects with a best overall response (BOR) of either confirmed partial response (PR), confirmed complete response (CR) or stable disease (SD) or non-CR/non-PD before crossover.

    Time frame: From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).

  7. Number of Participants With Adverse Events (AEs)

    Safety analyses were performed for subjects in the safety analysis population for each group. Unless otherwise specified, summaries were provided only for the on-treatment safety assessments, which are the assessments occurring or taken during the on-treatment period

    Time frame: From baseline to last dose date of study treatment + 30 days (an average of 7.5 months for the infigratinib arm and 5 months for the gemcitabine + cisplatin arm).

  8. Number of Participants With Serious Adverse Events (SAEs)

    Safety analyses were performed for subjects in the safety analysis population for each group. Unless otherwise specified, summaries were provided only for the on-treatment safety assessments, which are the assessments occurring or taken during the on-treatment period

    Time frame: From baseline to last dose date of study treatment + 30 days (an average of 7.5 months for the infigratinib arm and 5 months for the gemcitabine + cisplatin arm).

07

Results

Posted May 8, 2024

Participant flow

Participants with a diagnosis of advanced/metastatic or inoperable cholangiocarcinoma (CCA) with FGFR2 fusion/rearrangement were recruited to this open-label, randomized, controlled global study across Western Europe, North America, and Asia, based on documented evidence of FGFR2 genetic alteration. The first participant was treated on 18 March 2020. The data cutoff for the analysis was 02 March 2023.

Participant flow — Overall Study
MilestoneInfigratinib (BGJ398) 125 mgGemcitabine + Cisplatin
Started2919
Completed2917
Not completed02

Outcome measures

PrimaryProgression-free Survival (Central Imaging Assessment)

Defined as the time from randomization until date of disease progression by blinded independent central imaging assessment (Response Evaluation Criteria in Solid Tumors \[RECIST\] v. 1.1) or death, whichever occurs first.

Time frame:
From the time of randomization to end of treatment due to confirmed disease progression or death. Note: PFS is an event driven endpoint. Subjects without confirmed disease progression at the end of study were censored at their last valid tumor assessment.
Reported as:
Median · Months
Progression-free Survival (Central Imaging Assessment)
MonthsInfigratinib (BGJ398) 125 mgGemcitabine + Cisplatin
Progression-free Survival (Central Imaging Assessment)7.39 (0.03 to 12.85)8.02 (0.03 to 12.88)
SecondaryOverall Survival (OS) in Participants Treated With Infigratinib Versus Gemcitabine With Cisplatin

OS by investigator assessment, defined as time from date of randomization until death due to any cause

Time frame:
From the time of randomization to time of death. Note: OS is an event driven endpoint. Subjects who had not died (no record of death) or were lost to follow-up were censored at the date of last known to be alive.
Reported as:
Median · Months
Overall Survival (OS) in Participants Treated With Infigratinib Versus Gemcitabine With Cisplatin
MonthsInfigratinib (BGJ398) 125 mgGemcitabine + Cisplatin
Overall Survival (OS) in Participants Treated With Infigratinib Versus Gemcitabine With CisplatinNA (14.36 to NA)NA (8.02 to NA)
SecondaryInvestigator Assessed Progression Free Survival in Participants Treated With Infigratinib Compared to Gemcitabine and Cisplatin

Defined as the time from randomization until date of disease progression by site investigator (RECIST v1.1) or death, whichever occurs first.

Time frame:
From the time of randomization to end of treatment due to confirmed disease progression or death. Note: PFS is an event driven endpoint. Subjects without confirmed disease progression at the end of study were censored at their last valid tumor assessment.
Reported as:
Median · Months
Investigator Assessed Progression Free Survival in Participants Treated With Infigratinib Compared to Gemcitabine and Cisplatin
MonthsInfigratinib (BGJ398) 125 mgGemcitabine + Cisplatin
Investigator Assessed Progression Free Survival in Participants Treated With Infigratinib Compared to Gemcitabine and Cisplatin7.39 (0.03 to 20.24)5.19 (0.03 to 12.88)
SecondaryOverall Response Rate (ORR) Determined by Blinded Independent Central (BICR) and Investigator Assessment

ORR is defined as the proportion of subjects with a best overall response (BOR) of either confirmed partial response (PR) or confirmed complete response (CR) as assessed by BICR and the investigator according to RECIST v1.1 among patients with measurable disease at baseline

Time frame:
From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) Determined by Blinded Independent Central (BICR) and Investigator Assessment
ParticipantsORR By Central AssessmentORR By Investigator AssessmentORR by Central AssessmentORR by Investigator Assessment
Overall Response Rate (ORR) Determined by Blinded Independent Central (BICR) and Investigator Assessment11932
SecondaryBest Overall Response (BOR) Determined by Blinded Independent Central Assessment and the Investigator.

BOR was defined as the best response a subject ever achieved after study treatment prior to crossover and any subsequent anticancer therapy, complete response (CR) and partial response (PR) were claimed only if the criteria for each were met at a subsequent time point at least 4 weeks apart. In the case of stable disease (SD), measurements must have met the SD criteria at least once post-baseline no less than 6 weeks from the randomization date.

Time frame:
From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).
Reported as:
Count of participants · Participants
Best Overall Response (BOR) Determined by Blinded Independent Central Assessment and the Investigator.
ParticipantsBOR By Central AssessmentBOR By Investigator AssessmentBOR by Central AssessmentBOR by Investigator Assessment
Confirmed complete response0000
Confirmed partial response11932
Stable disease14191112
Progressive disease2023
Not done2132
SecondaryDuration of Response (DOR) Determined by Blinded Independent Central Assessment and the Investigator.

DOR is defined as the time from initiation of confirmed partial response (PR) or confirmed complete response (CR) to the time of confirmed progressive disease (PD) or death. If subjects do not reach PD or death before crossover, the DOR is censored at the last valid tumor assessment before crossover.

Time frame:
From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).
Reported as:
Median · Months
Duration of Response (DOR) Determined by Blinded Independent Central Assessment and the Investigator.
MonthsDOR By Central AssessmentDOR By Investigator AssessmentDOR by Central AssessmentDOR by Investigator Assessment
Duration of Response (DOR) Determined by Blinded Independent Central Assessment and the Investigator.5.59 (3.71 to NA)7.52 (3.71 to NA)NA (3.94 to NA)NA (8.08 to NA)
SecondaryDisease Control Rate (DCR=PR+CR+SD) Determined by Blinded Independent Central Assessment and the Investigator.

DCR is defined as the proportion of subjects with a best overall response (BOR) of either confirmed partial response (PR), confirmed complete response (CR) or stable disease (SD) or non-CR/non-PD before crossover.

Time frame:
From the time of randomization to end of study treatment (an average of approx.6.5 months [max: 23 months] for the infigratinib arm and approx. 4 months [max: 11-13 months] for the gemcitabine + cisplatin arm up to the time of termination of the study).
Reported as:
Count of participants · Participants
Disease Control Rate (DCR=PR+CR+SD) Determined by Blinded Independent Central Assessment and the Investigator.
ParticipantsDCR By Central AssessmentDCR By Investigator AssessmentDCR by Central AssessmentDCR by Investigator Assessment
Disease Control Rate (DCR=PR+CR+SD) Determined by Blinded Independent Central Assessment and the Investigator.25281414
SecondaryNumber of Participants With Adverse Events (AEs)

Safety analyses were performed for subjects in the safety analysis population for each group. Unless otherwise specified, summaries were provided only for the on-treatment safety assessments, which are the assessments occurring or taken during the on-treatment period

Time frame:
From baseline to last dose date of study treatment + 30 days (an average of 7.5 months for the infigratinib arm and 5 months for the gemcitabine + cisplatin arm).
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsInfigratinib (BGJ398) 125 mgGemcitabine + Cisplatin
Number of Participants With Adverse Events (AEs)2917
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

Safety analyses were performed for subjects in the safety analysis population for each group. Unless otherwise specified, summaries were provided only for the on-treatment safety assessments, which are the assessments occurring or taken during the on-treatment period

Time frame:
From baseline to last dose date of study treatment + 30 days (an average of 7.5 months for the infigratinib arm and 5 months for the gemcitabine + cisplatin arm).
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsInfigratinib (BGJ398) 125 mgGemcitabine + Cisplatin
Number of Participants With Serious Adverse Events (SAEs)100

Adverse events

Collected over From the the time of the first administration of study treatment through 30 days after their last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infigratinib (BGJ398) 125 mg0/29 (0%)10/29 (34.5%)29/29 (100%)
Gemcitabine + Cisplatin0/17 (0%)0/17 (0%)17/17 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventInfigratinib (BGJ398) 125 mgGemcitabine + Cisplatin
StomatitisGastrointestinal disorders2/290/17
COVID-19Infections and infestations2/290/17
Eye painEye disorders1/290/17
DysphagiaGastrointestinal disorders1/290/17
FatigueGeneral disorders1/290/17
SepsisInfections and infestations1/290/17
CalciphylaxisMetabolism and nutrition disorders1/290/17
HypercalcaemiaMetabolism and nutrition disorders1/290/17
HyperphosphataemiaMetabolism and nutrition disorders1/290/17
HypokalaemiaMetabolism and nutrition disorders1/290/17
Most frequent other events
Showing 10 of 150
Most frequent other events
EventInfigratinib (BGJ398) 125 mgGemcitabine + Cisplatin
HyperphosphataemiaMetabolism and nutrition disorders26/290/17
NauseaGastrointestinal disorders7/2911/17
ConstipationGastrointestinal disorders14/294/17
FatigueGeneral disorders12/298/17
DiarrhoeaGastrointestinal disorders13/295/17
Decreased appetiteMetabolism and nutrition disorders12/295/17
HypophosphataemiaMetabolism and nutrition disorders12/291/17
AlopeciaSkin and subcutaneous tissue disorders12/291/17
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders12/290/17
AnaemiaBlood and lymphatic system disorders5/297/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Infigratinib (BGJ398) 125 mgGemcitabine + CisplatinTotal
<=18 years000
Between 18 and 65 years211334
>=65 years8614
Age, Continuous
Age, Continuous(years)Infigratinib (BGJ398) 125 mgGemcitabine + CisplatinTotal
Mean54 ± 13.2258.2 ± 15.2555.8 ± 14.04
Sex: Female, Male
Sex: Female, Male(Participants)Infigratinib (BGJ398) 125 mgGemcitabine + CisplatinTotal
Female191029
Male10919
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Infigratinib (BGJ398) 125 mgGemcitabine + CisplatinTotal
American Indian or Alaska Native000
Asian7310
Native Hawaiian or Other Pacific Islander000
Black or African American101
White201434
More than one race000
Unknown or Not Reported123
Region of Enrollment
Region of Enrollment(participants)Infigratinib (BGJ398) 125 mgGemcitabine + CisplatinTotal
North America12719
Europe14822
Southeast Asia347
BMI
BMI(kg/m2)Infigratinib (BGJ398) 125 mgGemcitabine + CisplatinTotal
Mean28.41 ± 7.01826.83 ± 8.01927.79 ± 7.388
ECOG PS
ECOG PS(Participants)Infigratinib (BGJ398) 125 mgGemcitabine + CisplatinTotal
019827
1101121
2000
Primary site of cholangiocarcinoma
Primary site of cholangiocarcinoma(Participants)Infigratinib (BGJ398) 125 mgGemcitabine + CisplatinTotal
Common bile duct112
Intrahepatic bile duct281745
Other011

6 further baseline measures are reported on the registry.

08

Study locations

116 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • St. Joseph Heritage Healthcare
    Fullerton, California 92835, United States
  • USC Norris Cancer Center
    Los Angeles, California 90033, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Florida Hospital Medical Group
    Orlando, Florida 32804, United States
  • UF Health Cancer Center at Orlando Health
    Orlando, Florida 32806, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • University Medical Center - New Orleans
    New Orleans, Louisiana 70112, United States
  • Frederick Regional Healthcare Systems/James M. Stockman Cancer Institute
    Frederick, Maryland 21702, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Barbara Ann Karmanos Cancer Institute - Lawrence and Idell Weisberg Cancer Treatment Center
    Detroit, Michigan 48201, United States
  • Cancer and Hematology Centers of Western Michigan
    Grand Rapids, Michigan 49503, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Levine Cancer Institute - Charlotte
    Charlotte, North Carolina 28204, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45267, United States
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43202, United States
  • Charleston Oncology
    Charleston, South Carolina 29414, United States
  • Parkland Health and Hospital System
    Dallas, Texas 75343, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Baylor College of Medicine
    Houston, Texas 77096, United States
  • Chris O'Brien Lifehouse Hospital
    Camperdown, New South Wales, Australia
  • Blacktown Hospital
    Darlinghurst, New South Wales, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia, Australia
  • Monash Medical Centre
    Bentleigh East, Victoria, Australia
  • Peninsula & South Eastern Haematology and Oncology Group
    Frankston, Victoria, Australia
  • St John of God Hospital Subiaco
    Subiaco, Western Australia, Australia
  • Cliniques Universitaires Saint-Luc
    Bruxelles, Brussels 1200, Belgium
  • Grand Hopital de Charleroi
    Charleroi, 6000, Belgium
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • Cross Cancer Institute
    Edmonton, Alberta, Canada
  • Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • St. Josephs Health Centre
    Toronto, Ontario, Canada
  • Jewish General Hospital
    Montréal, Quebec H3T 1E2, Canada
  • Peking University People's Hospital
    Beijing, 100033, China
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Peking University Third Hospital
    Beijing, 100191, China
  • Hunan Cancer Hospital
    Changsha, 410006, China
  • Guangzhou First People's Hospital
    Guangzhou, 510080, China
  • Hubei Cancer Hospital
    Hubei, 430079, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, 110042, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Zhongshan, 510060, China
  • Hopital Henri Mondor
    Créteil, Val-de-Marne 94000, France
  • CHRU Dijon
    Dijon, 21000, France
  • Centre Georges-Francois Leclerc
    Dijon, 21079, France
  • Hopital Claude Huriez Rue Michel Polonovski (CHRU) Lille
    Lille, 59000, France
  • Groupement Hospitalier Edouard Herriot
    Lyon, 69437, France
  • Hopital Nord Franche-Comte
    Montbéliard, 25200, France
  • Groupe Hospitalier Archet I Et II
    Nice, 06202, France
  • Hopital Cochin
    Paris, 75014, France
  • Hôpital Saint Antoine
    Paris, 75571, France
  • L'Institut Mutualiste Montsouris
    Paris, 75674, France
  • Universitätsklinikum Tübingen
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Klinikum rechts der Isar der Technischen Universität München
    München, Bayern 81675, Germany
  • Klinikum Dortmund gGmbH
    Dortmund, 44137, Germany
  • University Clinic Heidelberg
    Heidelberg, 69120, Germany
  • Azienda Socio Sanitaria Territoriale di Cremona (ASST)
    Cremona, 26100, Italy
  • Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST
    Meldola, 47014, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • ASST Grande Ospedale Metropolitano Niguarda
    Milano, 20162, Italy
  • Istituto Oncologico Veneto - I.R.C.C.S.
    Padova, 35128, Italy
  • Policlinico Universitario Campus Biomedico Di Roma
    Roma, 00128, Italy
  • Pusan National University Hospital
    Pusan, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, Korea, Republic of
  • SMG - SNU Boramae Medical Center
    Seoul, 07061, Korea, Republic of
  • Samsung Medical Center
    Seoul, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
  • Severance Hospital Yonsei University Health System
    Seoul, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, Korea, Republic of
  • Ajou University Hospital
    Suwon-si, Korea, Republic of
  • Hospital Beatriz Angelo
    Loures, Lisboa 2674-514, Portugal
  • Hospital Garcia de Orta
    Almada, 2801-951, Portugal
  • Centro Hospitalar E Universitário de Coimbra EPE
    Coimbra, 3000-075, Portugal
  • Instituto Português de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra EPE
    Coimbra, 3000-075, Portugal
  • Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria
    Lisboa, 1649-035, Portugal
  • Hospital CUF Descobertas
    Lisboa, 1998-018, Portugal
  • Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.
    Lisbon, 1099-023, Portugal
  • Centro Hospitalar do Porto - Hospital de Santo António
    Porto, 4099-001, Portugal
  • Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
    Porto, 4200-072, Portugal
  • Centro Hospitalar de São João, E.P.E.
    Porto, 4200-319, Portugal
  • Hospital Oncologico, Puerto Rico Medical Center
    Rio Piedras, 00935, Puerto Rico
  • Hospital Universitario Virgen Macarena
    Sevilla, Andalucia 41009, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, Aragon 50009, Spain
  • Complejo Asistencial Universitario de Salamanca - Hospital Clinico
    Salamanca, Castilla Y Leon 37007, Spain
  • Hospital Universitario Germans Trias i Pujol
    Badalona, Cataluna 08916, Spain
  • Instituto Catalan de Oncologio ICO I'Hospitalet
    Barcelona, Cataluna 08907, Spain
  • Hospital Universitario Vall d'Hebrón - PPDS
    Barcelona, 08035, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario HM Sanchinarro - CIOCC
    Madrid, 28050, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
  • National Cheng Kung University Hospital
    Tainan City, Tainan 704, Taiwan
  • National Taiwan University Hospital - YunLin Branch
    Huwei, 632, Taiwan
  • Chang Gung Memorial Hospital - Kaohsiung
    Kaohsiung, 833, Taiwan

Showing the first 100 of 116 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Makawita S, K Abou-Alfa G, Roychowdhury S, Sadeghi S, Borbath I, Goyal L, Cohn A, Lamarca A, Oh DY, Macarulla T, T Shroff R, Howland M, Li A, Cho T, Pande A, Javle M. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol. 2020 Oct;16(30):2375-2384. doi: 10.2217/fon-2020-0299. Epub 2020 Jun 25. PubMed 32580579 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Mar 2023, 38 months.

Results were first posted in May 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2018
First posted
Dec 12, 2018
StartActual
Dec 27, 2019
Primary completionActual
Mar 2, 2023
CompletionActual
Mar 2, 2023
Results first posted
May 8, 2024
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03773302
Responsible party
Sponsor
First posted
Dec 12, 2018
Start date
Dec 27, 2019
Primary completion
Mar 2, 2023
Completion
Mar 2, 2023
Results posted
May 8, 2024
Last update
May 8, 2024

Study contacts

Clinical Development
study director · QED Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infigratinib

Start the discussion